HIGH-PERFORMANCE CELLULAR RADIOSENSITIVITY ASSAY COMBINED TO A POLYGENIC SCORE TO PREDICT LATE POST RADIOTHERAPY OVERREACTION IN CANCER PROSTATE PATIENTS: A PROOF OF CONCEPT. (December 2022)